The sales of Dendreon and three skincare brands will help the troubled drug maker to reduce its $30 billion debt burden.
A Canadian regulator issues a cease trade order after the troubled drug maker announces it would be late filing financial reports.
Howard Schiller says he is not to blame for the incorrect recognition of $58 million in revenue that has caused Valeant to restate its financial results.
The pharmaceuticals company also canceled its 2016 financial guidance and delayed filing its fourth-quarter earnings report.
The agonies and ecstasies of firms that are addicted to doing takeovers.
The takeover contest's outcome becomes unclear when we consider the conflict between the hedge fund’s objectives and the Allergan board's fiduciary duty.
